Anna Truppel-Hartmann

1.1k total citations
22 papers, 289 citations indexed

About

Anna Truppel-Hartmann is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Anna Truppel-Hartmann has authored 22 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Hematology and 9 papers in Molecular Biology. Recurrent topics in Anna Truppel-Hartmann's work include CAR-T cell therapy research (13 papers), Multiple Myeloma Research and Treatments (13 papers) and Protein Degradation and Inhibitors (7 papers). Anna Truppel-Hartmann is often cited by papers focused on CAR-T cell therapy research (13 papers), Multiple Myeloma Research and Treatments (13 papers) and Protein Degradation and Inhibitors (7 papers). Anna Truppel-Hartmann collaborates with scholars based in United States, France and Spain. Anna Truppel-Hartmann's co-authors include Jesús G. Berdeja, Nina Shah, Noopur Raje, Timothy Campbell, Melissa Alsina, Sundar Jagannath, David S. Siegel, Saad Z. Usmani, Nikhil C. Munshi and Yi Lin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Haematologica.

In The Last Decade

Anna Truppel-Hartmann

21 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Truppel-Hartmann United States	10	223	141	130	65	51	22	289
Carolyn C. Jackson United States	11	308 1.4×	183 1.3×	188 1.4×	90 1.4×	30 0.6×	41	399
Marion Subklewe Germany	6	180 0.8×	86 0.6×	114 0.9×	95 1.5×	19 0.4×	36	276
Kyle A. Udd United States	8	202 0.9×	121 0.9×	197 1.5×	51 0.8×	37 0.7×	25	307
Phaik Ju Teoh Singapore	8	189 0.8×	294 2.1×	175 1.3×	61 0.9×	31 0.6×	15	406
Cesar Rodriguez United States	8	171 0.8×	86 0.6×	164 1.3×	44 0.7×	14 0.3×	40	262
Marion Subklewe Germany	10	212 1.0×	71 0.5×	66 0.5×	65 1.0×	27 0.5×	24	257
Tiina Hannunen Finland	4	139 0.6×	100 0.7×	50 0.4×	125 1.9×	33 0.6×	4	285
Kathleen Ruehle United States	8	212 1.0×	78 0.6×	121 0.9×	62 1.0×	41 0.8×	24	291
Dana Průková Czechia	7	149 0.7×	139 1.0×	40 0.3×	53 0.8×	103 2.0×	14	296
Florian Eisele Germany	6	207 0.9×	41 0.3×	63 0.5×	89 1.4×	63 1.2×	12	259

Countries citing papers authored by Anna Truppel-Hartmann

Since Specialization

Citations

This map shows the geographic impact of Anna Truppel-Hartmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Truppel-Hartmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Truppel-Hartmann more than expected).

Fields of papers citing papers by Anna Truppel-Hartmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Truppel-Hartmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Truppel-Hartmann. The network helps show where Anna Truppel-Hartmann may publish in the future.

Co-authorship network of co-authors of Anna Truppel-Hartmann

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Truppel-Hartmann. A scholar is included among the top collaborators of Anna Truppel-Hartmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Truppel-Hartmann. Anna Truppel-Hartmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abonour, Rafat, Amani Kitali, A Trovato, et al.. (2024). P-002 Ide-Cel Real-World (RW) and Clinical Trial Long-Term Safety Experience: A Special Focus on Movement and Neurocognitive Treatment Adverse Events (MNT AEs) and Second Primary Malignancies (SPMs). Clinical Lymphoma Myeloma & Leukemia. 24. S40–S41.

Leleu, Xavier, Alfred Chung, Noopur Raje, et al.. (2024). P-045 Idecabtagene Vicleucel (ide-cel) in Patients (pts) With Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Front-Line (1L) Autologous Stem Cell Transplantation (ASCT): KarMMA-2 Cohort 2B. Clinical Lymphoma Myeloma & Leukemia. 24. S67–S67. 1 indexed citations

Raje, Noopur, Adam D. Cohen, Shaji Kumar, et al.. (2024). MM-493 Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) With Lenalidomide (R) Maintenance Versus R Maintenance Alone in Adult Patients With Newly Diagnosed Multiple Myeloma (NDMM) Who Have Suboptimal Response to Autologous Stem Cell Transplantation (ASCT): Phase 3 KarMMa-9 Trial. Clinical Lymphoma Myeloma & Leukemia. 24. S562–S563. 1 indexed citations

Alsina, Melissa, Madhav V. Dhodapkar, Jesús G. Berdeja, et al.. (2023). P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C. HemaSphere. 7(S3). e90596a3–e90596a3. 1 indexed citations

Raje, Noopur, Melissa Alsina, Nina Shah, et al.. (2022). OAB-007: Updated clinical and correlative results from the Phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and/or refractory multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 22. S4–S5. 1 indexed citations

Locke, Frederick L., et al.. (2022). CRC-403: A Phase 1/2 Study of bbT369, a Dual CD79a and CD20 Targeting CAR T Cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL). Blood. 140(Supplement 1). 12716–12717. 7 indexed citations

Usmani, Saad Z., Krina K. Patel, Parameswaran Hari, et al.. (2022). KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation. Blood. 140(Supplement 1). 875–877. 38 indexed citations

Locke, Frederick L., et al.. (2022). CRC-403: A phase 1/2 study of bbT369, a dual targeting CAR T-cell drug product with a gene edit, in relapsed and/or refractory B-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 40(16_suppl). TPS7580–TPS7580. 1 indexed citations

Raje, Noopur, David S. Siegel, Sundar Jagannath, et al.. (2021). Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study. Transplantation and Cellular Therapy. 27(3). S66–S67. 2 indexed citations

10.

Berdeja, Jesús G., Noopur Raje, David S. Siegel, et al.. (2021). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S397–S398. 2 indexed citations

11.

Raje, Noopur, Nina Shah, Sundar Jagannath, et al.. (2021). Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. Blood. 138(Supplement 1). 548–548. 66 indexed citations

12.

Manier, Salomon, Ankit Kansagra, Larry D. Anderson, et al.. (2021). Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.. Journal of Clinical Oncology. 39(15_suppl). 8036–8036. 4 indexed citations

13.

Kansagra, Ankit, Jesús G. Berdeja, Nina Shah, et al.. (2021). Characterization of Cytokine Release Syndrome (CRS) in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma (RRMM). Transplantation and Cellular Therapy. 27(3). S396–S397. 1 indexed citations

14.

Usmani, Saad Z., Jesús G. Berdeja, Anna Truppel-Hartmann, et al.. (2021). KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.. Journal of Clinical Oncology. 39(15_suppl). TPS8053–TPS8053. 17 indexed citations

15.

Rodríguez‐Otero, Paula, Jesús F. San Miguel, Larry D. Anderson, et al.. (2021). Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study. Blood. 138(Supplement 1). 2743–2743. 5 indexed citations

16.

Usmani, Saad Z., Jesús G. Berdeja, Anna Truppel-Hartmann, et al.. (2020). KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma. Blood. 136(Supplement 1). 18–19. 19 indexed citations

17.

Raje, Noopur, David S. Siegel, Sundar Jagannath, et al.. (2020). Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study. Blood. 136(Supplement 1). 37–38. 23 indexed citations

18.

Kansagra, Ankit, Jesús G. Berdeja, Nina Shah, et al.. (2020). Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma. Blood. 136(Supplement 1). 26–27. 15 indexed citations

19.

Cartron, Guillaume, Florence Hourcade‐Potelleret, Franck Morschhauser, et al.. (2015). Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. Haematologica. 101(2). 226–234. 30 indexed citations

20.

Bosch, Francesc, Thomas Illmer, Mehmet Turgut, et al.. (2014). Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood. 124(21). 3345–3345. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact